INTRODUCTION
With contemporary intensive therapies, a high proportion of acute leukemia patients will enter a morphologic CR, defined by the presence of o5% blasts in the BM. 1, 2 If no further therapy is given after entering a morphologic CR, essentially all patients will relapse, demonstrating that microscopy-based evaluations are incapable of detecting all tumor cells. More recently, various diagnostic techniques have been developed to detect, quantify and monitor 'minimal' amounts of residual disease (MRD)-invisible to the trained eye-in patients with morphologic CR. Of course, the term 'MRD' is somewhat misleading as it implies the persistence of minute amounts of malignant cells while, at the time of morphologic CR, it is estimated that patients may still harbor as many as B10 10 -10 11 leukemic cells. [3] [4] [5] The ability to quantitatively measure the amount of MRD at various times after attainment of CR offers a potentially powerful tool to guide subsequent treatment. Other reviews have focused on the role of MRD for risk stratification after achievement of an initial CR and on the use of MRD measurement to monitor patients while on chemotherapy. [6] [7] [8] [9] [10] [11] [12] [13] [14] Herein, we review the accumulating data on the prognostic and, likely, therapeutic role of MRD at the time of hematopoietic cell transplantation (HCT) for patients with acute leukemias. As will become apparent, ALL has so far been studied in more detail, but available information gathered from investigations in AML suggests that many principles regarding MRD apply to both diseases.
THE CONCEPT AND DETERMINATION OF MRD
The hypothetical value of measuring tumor loads comes from the notion of a close relationship between residual tumor burden and the likelihood of subsequent relapse ( Figure 1) . 3 Quantifying leukemic cells after therapeutic interventions should thus allow earlier recognition of disease persistence and could provide a tool for personalized decision-making, assigning high-risk patients to more intensive therapies and sparing low-risk patients toxicities from unnecessary treatments. 15 Several strategies have been devised to identify residual leukemic cells among normal hematopoietic cells based on numeric or structural chromosomal changes, gene mutations, Ag receptor rearrangements, abnormal gene expression, altered cell growth and immunophenotype abnormalities; 6, 7, [14] [15] [16] [17] Table 1 provides an overview of MRD measurement methodologies that have been exploited clinically. To be useful, MRD assays should reliably identify and quantify malignant cells with high sensitivity (at least 10 À 3 but ideally approaching 10
) and specificity throughout the disease course, be reproducible, and allow easy standardization across different laboratories. 6, 18 Although many techniques are limited one way or another, the clinical suitability of multiparameter flow cytometry (MFC)-and PCR-based approaches for MRD detection and quantification is now well documented. 6, 7, 13, 14, 16, 19 ALL or AML cells express immunophenotypic features ('leukemia-associated immunophenotypes') that can be used to distinguish them from normal hematopoietic cells in the vast majority (490%) of cases with a current sensitivity of detection of 10 . In addition to its wide applicability in acute leukemia, advantages of MFC as a methodology include its rapid turnaround time, specificity and ability to distinguish live from dead cells and provide quantitative results; however, although flow cytometers are readily available nowadays, specific expertise is required to perform MFC-based assays reliably and well, and assay standardization is challenging. Even higher detection sensitivities (up to 10 À 6 ) can currently be achieved with PCR-based approaches. PCR amplification of Ig or TCR genes allows MRD monitoring in B90% of B-and T-cell ALLs, and a very small subset (B10%) of AMLs, in a quantitative manner but requires, before the era of massive parallel sequencing, the use of patient-specific reagents. The amplification of recurrent gene fusions or somatic mutations as an alternative method is limited to subsets of patients (B40-50% of ALL and B70% of AML), making this approach unavailable for many patients with acute leukemia. Results from MFC-and PCR-based assays typically correlate well, 7 and the combined use of two or more assays may offset their individual limitations and broaden the range of patients that can be studied. 7 However, cases with discordant findings between individual MRD assays, for example MFC and cytogenetics, do exist. 20 Theoretical limitations of current MRD assays include the inability to distinguish viable from dead cells (for PCR-based methods) and to identify the subset of leukemia cells with selfrenewing and disease-perpetuating capability. 7 Furthermore, accurate whole-body tumor burden quantification via a single, small BM or peripheral blood sample requires homogenous tumor cell distribution, a condition that might not be met at remission. 21, 22 Nevertheless, for both ALL and AML, persistence of MRD at various stages during and after curative intent chemotherapy has now repeatedly been associated with higher risk of relapse and inferior survival, thereby largely dismissing these concerns. 7, 9, 13 PROGNOSTIC SIGNIFICANCE OF PRE-HCT MRD As transplantation is often considered for acute leukemia patients in morphologic CR, it is important to define the significance of MRD in this situation. While the negative impact of morphologic leukemia burden at the time of HCT is well established, [23] [24] [25] [26] the first indication of the prognostic role of submicroscopic tumor burdens in patients with ALL in this situation was provided by Uckun et al. 27 By combining flow cytometry-based cell sorting with in vitro progenitor cell assays to quantify MRD, these investigators observed an inverse relationship between residual progenitor cell numbers and remission duration after autologous transplantation (AutoHCT), an association that was later confirmed in an independent study; 28 the use of effectively-purged autografts strongly argued for this association to reflect the role of in vivo tumor burden rather than result from reinfused leukemia cells contained in autografts. 27 Subsequently, a large number of retrospective and prospective studies investigated the role of MRD in ALL, typically measured via PCR-based detection of Ig or TCR rearrangements or via MFC before AutoHCT (Table 2) or allogeneic HCT (AlloHCT; Table 3 ). These studies, in general, reached similar conclusions-the presence of MRD at the time of Auto-or AlloHCT for ALL has prognostic significance-although comparability of findings across studies is limited because of differences in study populations, treatment regimens and MRD detection methods. Even results from individual studies need to be interpreted cautiously as treatments were generally not standardized within study cohorts, and selected patients were included in these analyses. Nevertheless, these studies uniformly found excellent long-term outcomes for patients without detectable MRD (that is, 'MRD À ' patients) undergoing myeloablative AlloHCT, with 2-5 year estimates of EFS, relapse-free survival and OS often in the 70-80% range, and more recent series suggesting even better outcomes. [29] [30] [31] [34] [35] [36] [37] [39] [40] [41] [42] [43] [46] [47] [48] [49] Almost without exception, the outcomes for patients with detectable MRD (that is, 'MRD þ ' patients) were significantly inferior, with long-term estimates of EFS of 0-30% and OS of 30-50%, respectively. Although data are more limited for AutoHCT, available information suggests that MRD À patients may have relatively good disease control that appears to approach that seen after AlloHCT, at least in the subset of leukemias that do not harbor the Philadelphia chromosome; on the other hand, MRD þ ALL patients experience exceedingly high rates of relapse after AutoHCT. 27, 28, 33, 44, 45 In acute promyelocytic leukemia (APL), MRD is almost exclusively assessed via PCR-based detection of the PML/RARA transgene, and several studies have demonstrated that APL patients who are MRD þ at AutoHCT have inferior outcomes than MRD À patients. 50, 51 In contrast, the prognostic role of pre-HCT MRD in non-APL AML is primarily studied via MFC-based assays to detect and quantify MRD. 46, 47, [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] Nevertheless, as summarized in Table 4 , more recent series show that both pediatric and adult patients with non-APL AML who are MRD À by current sensitive methods have excellent outcomes following myeloablative AlloHCT, with 2-5 year OS estimates around 75-80%. 47, 58, 61 For such patients, even AutoHCT may result in good disease control, with some studies showing 5-year OS estimates in the 60-70% range. 57, 59 On the other hand, MRD þ patients fair significantly worse with either type of HCT, with particularly high rates of relapse following AutoHCT. 46, 47, [53] [54] [55] [57] [58] [59] [60] [61] Not surprisingly, MRD is associated with other adverse risk factors, such as older age, poor-risk cytogenetics, leukemia arising from an antecedent hematologic disorder or after chemo-/ D is e a s e p e r s is t e n c e V e r y e a r ly r e la p s e E a r ly r e la p s e L a t e r e la p s e V e r y la t e r e la p s e radiotherapy and a multidrug resistance phenotype. 53, 57, 61, 62 However, MRD appears to bear significance as an independent prognostic marker, as suggested by multivariate regression modeling in many of the studies. [27] [28] [29] 36, 37, 39, [42] [43] [44] [47] [48] [49] 53, 54, 57, [59] [60] [61] The association between MRD and risk of BM relapse is likely 'dose-dependent' in ALL 27, 28, 36, 37, 41, 42, 44, 47, 63 and, possibly, AML, 53, 54, 60 while MRD assessments may fail to predict extramedullary relapse accurately. 32, 45 Interestingly, evidence from logistic regression models suggests that the relative level of MRD has more impact on survival in ALL than in AML. 47 Many open questions remain to be addressed in future studies. Both the intensity of the preparative regimen and a GVL effect contribute to the elimination of tumor during the transplant process. Thus, one might hypothesize that the impact of the presence of MRD at the time of transplant will be greater with the use of reduced-intensity conditioning regimens or in the setting of T-cell depleting approaches. Indeed, a prognostic role of MRD before reduced-intensity conditioning-based AlloHCT is suggested by two studies on primarily adult patients with acute leukemia. 64, 65 Somewhat surprisingly, the effect appeared modest and was no longer seen after adjustment for other factors; however, as several different techniques were used to assess MRD, 64 including some that lack high sensitivity, methodological limitations may have skewed the findings toward the null. Likewise, although different sources of hematopoietic stem cells and immuno suppressive regimens have been utilized, the interplay between these factors and MRD has not been conclusively established but is likely important, as we will discuss in a later section. 
MRD: SURROGATE FOR THERAPEUTIC RESISTANCE OR MARKER FOR RISK-STRATIFIED THERAPY?
Despite the convincing evidence of pre-HCT MRD being a predictor of an increased risk of post-transplant relapse in acute leukemia, it has not been definitively established whether MRD information should be used for risk-stratified treatment allocation. Differences in pre-HCT MRD may not only quantify residual tumor burden but also serve as a surrogate for the inherent sensitivity of leukemia cells to therapy. Thus, being MRD þ after intensive induction/consolidation therapy may simply mark patients that are unlikely to be cured with subsequent therapies, especially as many available therapies do not fundamentally differ from one another. Consequently, reducing the quantity of inherently resistant cells-even (temporarily) below the level of disease detection-might not improve the prospect of cure. Further, additional therapy to reduce the tumor burden in MRD þ patients is likely associated with a risk of complications (for example, organ toxicities or infections) that could delay or prevent transplantation, increase transplant-related mortality, and offset any potential benefit of improved disease control. Nonetheless, the increased risk associated with MRD þ status at the time of transplant is a challenge that invites clinical study.
USING PRE-HCT MRD TO TAILOR THERAPY IN ACUTE LEUKEMIA
Assuming a benefit to intensified therapy for MRD þ patients, questions regarding optimal strategy arise: (1) Should the leukemic burden be reduced through additional treatment given before transplantation, that is, should achievement of a MRD À state pre-transplant be the goal for each patient? (2) Should the conditioning regimen be intensified? (3) Should every effort be undertaken to find a suitable donor for a MRD þ patient to avoid AutoHCT and allow GVL effects, and should immunosuppression be reduced to maximize this immunological reaction even at the expense of increased GVHD? And (4) Should additional immunological and/or non-immunological anti-leukemia treatment be given after transplantation? The latter may be particularly warranted in the setting of persistent or newly developed MRD after transplantation, because numerous studies have established that post-HCT MRD detected by PCR, flow cytometry, or (as a surrogate) levels of mixed chimerism accurately identifies a subset of patients at high risk for relapse and poor outcome. 16, 17, [33] [34] [35] 40, 63, [66] [67] [68] [69] [70] [71] [72] [73] As there are no data available from controlled trials addressing these questions, inferences need to be made from observational studies that compare subgroups 
Significance of MRD for HCT SA Buckley et al (for example, those who received more or less intense transplant regimens) or contrast study findings with historic controls. Nevertheless, a number of principles seem to emerge (Table 5) , as discussed in the following section.
Additional Pre-HCT Therapy The utility of MRD information to guide risk stratification after initial induction/consolidation therapy is under active investigation and is currently perhaps best supported by data in APL, where the use of all-trans retinoic acid (ATRA)-based therapy or arsenic trioxide at molecular relapse (that is, PCR-positivity for PML/RARA transcript) can prevent progression to overt disease relapse. [74] [75] [76] There is also some evidence in non-APL AML and ALL that treatment intensification (early HCT and/or earlier/additional induction therapy) for patients who are MRD þ after initial therapy may improve outcomes, at least when compared with contemporary cohorts or those MRD þ patients that did not receive the intensified therapy. [77] [78] [79] Some evidence also suggests benefit of tyrosine kinase inhibitors in BCR/ABL þ ALL with MRD. Significance of MRD for HCT SA Buckley et al
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As MRD levels decrease or become undetectable with intensified therapy, one could postulate that this benefit might translate into improved post-HCT outcomes. Indeed, convincing data to extrapolate a benefit of additional pre-HCT therapy may come from a phase 2 trial with blinatumomab, a bispecific single-chain Ab targeting CD19, in patients with B-lineage ALL having chemotherapy-refractory MRD. 81 In this study, 16 out of 20 MRD þ patients became MRD À after treatment with blinatumomab, and none of the 8 patients subsequently undergoing AlloHCT experienced post-HCT relapse. Although not all patients were responsive to Ab therapy, this finding suggests that elimination of MRD with blinatumomab may improve post-HCT outcomes of patients that otherwise would have been MRD þ at transplantation, but larger studies will be required to conclusively test this possibility. 81 Intensification of conditioning regimen Modulation of conditioning intensity constitutes an appealing approach of risk-adapted therapy, particularly if augmentation occurs via therapeutics that are non-cross-resistant with conventional chemotherapeutics, such as (radio)immunotherapy or molecularly targeted agents. So far, however, this concept has not been tested clinically, and the risk/benefit ratio with increased treatment-related morbidity/mortality remains unknown. Conversely, because adequate disease control might be maintained, outcomes for MRD À patients could perhaps be improved through use of less intensive conditioning regimens.
Allowing and maximizing GVL effects Although no truly randomized studies have compared the outcomes of MRD þ patients following AutoHCT or AlloHCT, a few series with transplant assignment based on donor availability have indicated that the outcomes of ALL or AML patients with pre-HCT MRD are better if they undergo AlloHCT, 33, 45, 58, 59 suggesting the importance of immunological anti-leukemia (GVL) effects. Consistent with this concept, at least in ALL, is the observation that patients who developed acute and/or chronic GVHD had a lower relapse risk compared with those without GVHD. 31, 34, 36, 63 Also in line with this notion, findings from several studies suggested that ALL patients with MRD at the time of HCT who subsequently survived until the study end-point more likely received unmanipulated rather than T-cell-depleted allografts. 29, 36 Besides assigning MRD þ patients to AlloHCT, these data suggest a role of transplantation with minimized immunosuppression or use of pre-emptive immunotherapy, or individualized, adoptive immunotherapy strategies (for example, Ag-specific T-cells or tumor vaccines) when further developed, 16 as a means to augment the alloreactive potential of transplanted cells. Repeated observations indeed suggested an anti-leukemia effect of such an approach, at least if used at very-low tumor burden. [82] [83] [84] Bader et al. 69 initially reported in a prospective study that, among 46 ALL patients with increasing mixed chimerisms after AlloHCT, the 31 subjected to immunotherapy (withdrawal of immunosuppression and/or low-dose donor lymphocyte infusion (DLI)) had a significantly better 3-year EFS than the 15 who did not receive immunotherapy (37% vs 0%, Po0.001). A follow-up study from the same group confirmed these findings by documenting a probability of EFS of 46% vs 0% for patients with mixed chimerisms receiving (n ¼ 13) vs not receiving (n ¼ 7) immunotherapy, with an EFS estimate of 71% for the subset of patients transplanted while in CR. 85 More recently, Yan et al. 86 reported on 105 patients with standard-risk acute leukemia (both ALL and AML) that were MRD þ after AlloHCT while in CR1 or CR2. In addition to modified immunosuppression, these patients were non-randomly assigned to either IL-2 (n ¼ 49) or DLI with/without IL-2 (n ¼ 56). Patients receiving DLI with/ without IL-2 had outcomes that were similar to those of 709 MRD À patients who did not receive pre-emptive immunotherapy and had a significantly lower risk of relapse and improved DFS than MRD þ patients receiving IL-2 only. 86 This encouraging experience is contrasted by observations of more limited and largely temporary effects of such pre-emptive measures in acute leukemia, suggesting insufficiency to prevent overt relapse in many patients. 35, 39, [87] [88] [89] [90] Additional (pre-emptive) post-HCT therapy Useful additional post-HCT therapy could encompass conventional chemotherapies (ideally non-cross-resistant to those used for prior therapies), Ab-based therapeutics, epigenetic modifying drugs and/or molecularly targeted agents. Supporting this strategy, Platzbecker et al. 91 observed that 16 out of 20 patients with CD34
þ AML or myelodysplastic syndromes who received the DNA methyltransferase I inhibitor, azacitidine, after they experienced a decrease in CD34 þ donor chimerisms to o80% responded with either increasing donor chimerism or stabilization thereof. Although, at the time of data cutoff, 13 of 20 patients had relapsed within a median of 231 (range, 56-558) days, a comparison with historic controls suggested that azacitidine could at least substantially delay, and in some cases possibly prevent, relapses. 91 A conceptually attractive strategy is the use of molecularly targeted therapeutics, for example, the use of all-trans Table 5 . Emerging principles of risk-stratified therapeutic approaches based on Pre-HCT MRD
MRD
þ patients As outcomes after AutoHCT are extremely poor and perhaps not better than with conventional chemotherapy, MRD þ patients should be assigned to AlloHCT if at all possible as this seems to provide a survival advantage and may cure a subset of these patients. For AlloHCT, unmanipulated (T-cell replete) grafts should be used, and immunosuppression should be kept at a minimum to optimize GVL effects. If patients remain MRD þ , or become MRD þ after AlloHCT, pre-emptive immunotherapy (for example, rapid withdrawal of immunosuppression and/or DLI) should be considered in the window before development of overt, morphologic disease relapse. Clinical trials should assess the value of pre-emptive non-immunological therapy, for example, with non-cross-reactive chemotherapeutics or molecularly targeted drugs. Some data can be extrapolated to suggest that additional pre-HCT therapy with non-cross-resistant agents might improve post-HCT outcome. As this treatment strategy likely leads to a delay in transplantation, it should primarily be considered in the setting of a clinical trial. The effect of intensified/augmented conditioning regimens in MRD þ patients is unknown but should be amenable to testing in future clinical trials.
À patients The outcome after myeloablative AlloHCT is excellent, with the majority of patients being alive and disease-free 3-5 years after transplantation. Although it is unclear whether AutoHCT (or AlloHCT with RIC or T-cell-depleted grafts) could replace AlloHCT in some subsets of MRD À patients to avoid complications of the latter, AutoHCT is sufficient and leads to adequate disease control in many MRD À patients, and AutoHCT could be considered if AlloHCT is not feasible.
Abbreviations: AlloHCT ¼ allogeneic HCT; AutoHCT ¼ autologous HCT; RIC ¼ reduced-intensity conditioning.
Significance of MRD for HCT SA Buckley et al retinoic acid in APL-its efficacy is suggested by case reports in this situation 92 -or tyrosine kinase inhibitors in BCR/ABL þ acute leukemias, and this approach is under active investigation. The validity of this approach was suggested by a prospective, multicenter study on 27 adults with BCR/ABL þ ALL who received imatinib upon MRD detection after AlloHCT. 93 BCR/ABL transcripts became undetectable in 14 (52%) of patients after a median of 1.5 months, and these patients remained in molecular remission for the duration of imatinib therapy. 93 Other observations were less encouraging, however, and suggested a more limited and temporary benefit of tyrosine kinase inhibitors, when used in isolation. 39, 94 
CONCLUSIONS
The cumulative evidence convincingly demonstrates that MRD at the time of transplantation is a powerful, independent predictor of adverse outcome in patients with acute leukemia, and that monitoring MRD post transplant provides prognostically relevant information. On the other hand, it is currently unclear how the MRD status at the time of transplantation and at subsequent times post transplant should guide therapeutic decisions. One important point that should not be missed in the discussion about MRD is that you cannot study something you cannot measure. Before the development of MRD measurements, there was no easy method for studying attempts to further reduce tumor burden in patients with leukemia in clinical remission. We now have that capability, and the availability of reliable MRD measures pre-and post transplant provides the clinical transplant community with a great opportunity that should be exploited.
Even with the limited data at hand, there are several clinical decisions that should be influenced by MRD measurements. As summarized in Table 5 , available data suggest that MRD þ patients should preferentially be assigned to AlloHCT, which can cure a subgroup of these patients, perhaps particularly if unmanipulated (T-cell replete) grafts and/or minimized immunosuppression are used to optimize GVL effects. Furthermore, emerging data suggest that additional therapy with non-cross-resistant agents to decrease residual tumor burden before transplantation in MRD þ patients might be beneficial. Finally, some studies hint at immunotherapy (for example, rapid withdrawal of immunosuppression and/or DLI) as means to prevent overt relapse if patients remain, or become, MRD þ after HCT. Admittedly, the level of evidence underlying these considerations is currently relatively low, and data from well-controlled prospective clinical trials are needed to strengthen these recommendations.
FUTURE DIRECTIONS
Although a number of markers and techniques have proven useful for MRD detection in patients with acute leukemia and have entered clinical practice, the list of suitable MRD markers will likely expand significantly in the future, and new technologies will further improve the sensitivity of MRD detection. 13, 46, [95] [96] [97] As the sensitivity, specificity and timing of MRD assays is critical, the development of standardized methods of MRD detection and analysis is an important step toward optimized use of this tool, and efforts in that direction are under way. 11, 13, 16, 98, 99 All transplant centers should be encouraged to participate in the development of standardized tools and adopt them as soon as they are available.
Given the abundance of relatively consistent data on the prognostic role of MRD in acute leukemia, future studies should focus on testing of MRD-directed risk-stratified therapeutic strategies. For example, one can imagine a study in which patients with AML in first remission who are MRD þ are randomized to either directly proceeding to transplantation vs receiving an additional round of novel chemotherapy before transplant. Or a trial might address whether intensification of the preparative regimen for MRD þ patients improves outcome. Additionally, the question could be addressed of whether therapy can be reduced in some or all MRD À patients, for example, by assigning them to AutoHCT or reduced-intensity conditioning conditioning to avoid toxicities. Future studies could also examine potential new applications of serial MRD measurements in the post-transplant setting; for example, their role as a means of measuring the effectiveness of post-transplant-targeted chemotherapies or immunotherapies in MRD þ patients could be tested.
As the use of MRD measurements expands, the financial impact of MRD monitoring may come under increased scrutiny. To respond to this important concern, it will be the responsibility of the transplant community to continue to compile evidence about the utility of MRD measurements. An important step in this direction is agreement on standardized measurements and timing of measurements. Such standardization will allow comparisons between studies and treatment approaches, and will help in the documentation of the importance of MRD measurements. More compelling will be the development of cooperative group-or network-based studies in which MRD measurements are needed, at a minimum, for risk stratification, but more ambitiously, as part of the treatment algorithm. Such studies would hopefully lead to the conclusion reached by Goulden et al.
